Chronic refractory cough is a persistent cough lasting over eight weeks despite treatment, significantly impacting patients' quality of life. It accounts for approximately 2%-18% of chronic cough cases worldwide. With a growing demand for advanced therapies, pharmaceutical companies are increasingly focusing on chronic refractory cough drug candidates. Recent advancements include neuromodulators, P2X3 purinoceptor antagonists, and novel anti-inflammatory agents. The pipeline for these treatments is expected to expand as clinical trials advance, regulatory approvals increase, and awareness of the condition improves.
Major companies involved in the chronic refractory cough pipeline drugs market include Trevi Therapeutics, Bellus Health Inc., Nocion Therapeutics, and others.
Leading drugs currently in the pipeline include BLU-5937, Nalbuphine ER, NOC-110, and others.
Advancements in P2X3 receptor antagonists, coupled with a rise in clinical trial activity and growing regulatory support, are driving progress in the chronic refractory cough pipeline landscape.
The Chronic Refractory Cough Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into chronic refractory cough therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic refractory cough. The chronic refractory cough report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic refractory cough pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic refractory cough treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic refractory cough.
Chronic refractory cough is a persistent cough lasting over eight weeks that does not respond to standard treatments. It often results from heightened nerve sensitivity in the airways, triggered by infections, allergies, or acid reflux. It can significantly impact daily life, causing discomfort, sleep disturbances, and social embarrassment.
Chronic refractory cough treatments focus on symptom relief. Options include neuromodulators like gabapentin, speech therapy, and cough suppression techniques. Emerging therapies, such as P2X3 receptor antagonists, target nerve hypersensitivity. Lifestyle modifications, including hydration and avoiding irritants, can help manage symptoms effectively.
The global prevalence of chronic cough is estimated to be between 2% and 18%. A cough lasting more than eight weeks is classified as chronic and affects approximately 10% of adults in the United States. Web-based National Health and Wellness Surveys report a 12-month prevalence of around 5% in Japan, Germany, the United States, and Spain. In Spain, the estimated lifetime prevalence is 8.2%, impacting 3.3 million adults.
This section of the report covers the analysis of chronic refractory cough drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total chronic refractory cough clinical trials.
The drug molecule categories covered under the chronic refractory cough pipeline analysis include small molecules, monoclonal antibodies, RNA-based therapies, peptide antagonists, and combination therapies. The chronic refractory cough report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic refractory cough.
The EMR report for the chronic refractory cough drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic refractory cough therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic refractory cough clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic refractory cough. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic refractory cough drug candidates.
BLU-5937, currently being investigated in a Phase III study sponsored by Bellus Health Inc. (a GSK company), targets refractory chronic cough. It works by inhibiting P2X3 receptors on sensory neurons to reduce cough reflex hypersensitivity. The study aims to assess its efficacy in reducing 24-hour cough frequency.
Nalbuphine ER (NAL ER), developed by Trevi Therapeutics, is being evaluated for the treatment of refractory chronic cough (RCC). It modulates the cough reflex arc through its dual mechanism as a kappa agonist and mu antagonist (KAMA). The objective of this Phase II study is to assess its efficacy and safety in RCC patients.
NOC-110 is undergoing Phase II clinical development for refractory or unexplained chronic cough. The clinical trial, conducted by Nocion Therapeutics, aims to evaluate its efficacy, safety, and tolerability. NOC-110, an inhalation powder, works by silencing activated nociceptors through sodium channel blockade, potentially offering superior antitussive effects compared to P2X3 antagonists.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Chronic Refractory Cough Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for chronic refractory cough. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic refractory cough collaborations, regulatory environments, and potential growth opportunities.
Chronic Refractory Cough (CRC) Epidemiology Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share